Organizing Committee

• Organizing Chair:
  Margit Malatschnig, Techkonnex – High-Tech Promotion, Vienna (A)
  Scientific Chairs:
  Andreas Zimmer, University of Graz (A)           Ruth Prassl, Medical University of Graz (A)

Scientific Advisory Board Members

(in alphabetical order)

• Ellis-Behnke Rutledge, Medical Faculty Mannheim of the Ruprecht-Karls-University Heidelberg, Director, Nanomedicine Translational Think Tank, MIT - Massachusetts Institute of Technology, Dept of Brain & Cognitive Sciences (Germany/USA)
• Borchard Gerrit, University of Geneva, President, Swiss Academy of Pharmaceutical Sciences (SAPhS), European Federation of Pharmaceutical Sciences (EUFEPS), (Switzerland)
  
• Falk Andreas, EURO-NanoTox, BioNanoNet Forschungsgesellschaft mbH, Graz (A)
• Ferrari Mauro, President of the Alliance for NanoHealth, The Methodist Hospital Research Institute, Houston (USA)
• Gabor Franz, Faculty of Life Sciences, Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna (A)
• Groth Thomas, Martin Luther University Hall-Wittenberg, Biomedical Materials Group, Halle (D)
• Gruner George, University of California Los Angeles, Nano-Biophysics Group (USA)
• Haick Hossam, Technion - Israel Institute of Technology, Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Haifa (Israel)
• Haupt Karsten , Compiègne University of Technology, CNRS Institute Enzyme and Cell Engineering, Compiègne (France)
• Hanes Justin, The Center of Nanomedicine, Wilmer Eye Institute, John Hopkins School of  Medicine, Baltimore (USA)
• Helbich Thomas, Medical University Vienna - General Hospital Vienna,  Department of Radiology, Head of Molecular and Gender Imaging, Vienna (Austria)
• Hellmich Christian, TU Wien, Institute for Mechanics of Materials and Structures, Vienna (A)
• Kirkpatrick C. James, Johannes Gutenberg University, Institute of Pathology, Mainz (D)
• Kompella Uday B., University of Colorado Anschutz Medical Campus, Denver (USA)
• Knoll Wolfgang , Austrian Research Centers GmbH – ARC, Scientific Managing Director (A)
• Langer Robert, Koch Institute for Integrative Cancer Research at MIT-Massachusetts Institute of Technology, Harvard-MIT Department Health Science and Technology (USA)
• Meisel Hans-Jörg, BG-Kliniken Bergmannstrost, Klinik für Neurochirurgie/Neurozentrum, Halle (D)
• Moghimi Moein, Centre for Pharmaceutical Nanotechnology and Nanotoxicology, Department of Pharmacy, University Copenhagen, Copenhagen (Denmark)
• Nehrer Stefan, Danube University Krems, Department Clinical Medicine and Biotechnology (A)
• Patri Anil K., FDA -Food and Drug Administration, National Center for Toxicological Research, Washington D.C. Metro Area (USA)  
• Prassl Ruth, Medical University of Graz, Institute of Biophysics, Graz (A)
• Pankhurst Quentin, University College London, Centre for Materials Research, Institute of Biomedical Engineering, Faculty of Engineering, London (United Kingdom)
• Redl Heinz, Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Austrian Cluster for Tissue Regeneration, Vienna (Austria)
• Singer Christian F. , Medical University Vienna, Head of Senology at Department of Obstetrics and Gynaecology, Vienna (Austria)
• Urban Gerald, IMTEK - Institute for Mikrosystem Technology, University of Freiburg (D)
• Walpoth Beat, Cardiovascular Research Service of Cardiovascular Surgery, Geneva University Hospital (CH)
• Weber Viktoria, Danube University Krems, Vice-Rector for Research, Krems (Austria)
• Zimmer Andreas, University of Graz, Institute of Pharmaceutical Sciences, Department of Pharmaceutical Technology, Graz (A)